Expert Advice, Articles & Blogs XiFin EXCELLENCE

Forward Thinking – Optimistic Outlook for Molecular Diagnostics

February 1, 2013

Like NIH, the AMA shifts into gear seeking stakeholder input and technology solutions to meet the demands of the fast paced developments in molecular diagnostics.

XiFin supports the concept of transparency and open standards for exchanging data with physicians, providers and payors as facilitated by a web based registry. Rapid advancements in molecular diagnostics necessitate the ability to provide agile coding and granularity. While the McKesson Z code will be voluntary, it provides a starting point for developing an optimal solution. We at XiFin are encouraged that the AMA is taking a leadership role in recognizing the paradigm shift in diagnostics and with their pro-active approach to re-engineering a process to effectively meet changing demands. We believe forward thinking entities like the AMA and NIH will establish the gold standard in coding coupled with a rich directory that will serve the healthcare industry well for its future needs, while innovative technology companies will continue to deliver advanced capabilities needed to navigate the information highway.

 

PiperJaffray issued an Industry Note yesterday that seems to concur with our view: “Given there are no changes to AMA’s 101 molecular diagnostic CPT codes currently being assigned reimbursement rates from Medicare Contractors, we do not anticipate any impact to this ongoing process. In our view, the primary benefit from this partnership will be increased industry clarity with the broad set of Z-Codes mapped to a smaller set of AMA CPT codes”

Sign up for Blog Alerts